¼¼°èÀÇ ¾ÏÁ¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå º¸°í¼­(2025³â)
Cancer Tumor Profiling Global Market Report 2025
»óǰÄÚµå : 1821540
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,362,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,196,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,031,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾ÏÁ¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 13.8%·Î 251¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº ¾Ï Ä¡·á¿¡¼­ ¸é¿ª ¿ä¹ý ¹× ¸é¿ª ÇÁ·ÎÆÄÀϸµÀÇ È®´ë, ¾×ü»ý°Ë ¹× ºñħ½ÀÀû Á¾¾ç ÇÁ·ÎÆÄÀϸµ ¹æ¹ýÀÇ °³¹ß, º¸´Ù »ó¼¼ÇÑ Á¾¾ç Ư¼º ºÐ¼®À» À§ÇÑ ´ÜÀÏ ¼¼Æ÷ ½ÃÄö½ÌÀÇ Ã¤ÅÃ, ¾Ï °ËÁø ¹× Á¶±â ¹ß°ß ÇÁ·Î±×·¥ÀÇ È®´ë, Èñ±Í¾Ï ¹× Èñ±Í¾Ï ¾ÆÇü ÇÁ·ÎÆÄÀϸµ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Á¾¾ç ÇÁ·ÎÆÄÀϸµÀÇ ÀÏ»ó ÀÓ»óÀ¸·ÎÀÇ ÅëÇÕ, ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ¹ßÀü, µ¥ÀÌÅÍ ºÐ¼®¿¡¼­ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕ, ¸ÂÃãÀÇ·á¿Í Ç¥ÀûÄ¡·áÁ¦ °³¹ß, À¯Àüü ºÐ¼®°ú Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼úÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·üÀ» 13.8%·Î ¿¹ÃøÇÑ °ÍÀº Áö³­¹ø ¿¹Ãøº¸´Ù 0.2% ¼ÒÆø Ç϶ôÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ¿¡ ±âÀÎÇÕ´Ï´Ù. °ü¼¼ ºÎ°ú´Â ij³ª´Ù¿Í ½º¿þµ§¿¡¼­ ¼öÀԵǴ ¸ÖƼ¿À¹Í½º ÇÁ·ÎÆÄÀϸµ ¼­ºñ½º¿Í ÀΰøÁö´É(AI) ±â¹Ý Á¾¾ç ºÐ¼® ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ Á¢±ÙÀ» Á¦ÇÑÇϰí, °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ ¼±ÅñÇÀ» À§ÇùÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¹Ì±¹ÀÇ Á¤¹ÐÀÇ·á¿¡ ½É°¢ÇÑ ¹®Á¦¸¦ ¾ß±âÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼¿Í ¹«¿ª ±äÀå°ú Á¦ÇÑ Áõ°¡·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀº ´õ¿í ±¤¹üÀ§ÇÏ°Ô ³ªÅ¸³¯ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°è¿¡¼­ ¾Ï ¹ßº´·ü Áõ°¡´Â ¾Ï ¹× Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ÏÀº ü³» ƯÁ¤ ¼¼Æ÷°¡ ÅëÁ¦ÇÒ ¼ö ¾øÀ» Á¤µµ·Î Áõ½ÄÇÏ¿© ´Ù¸¥ ºÎÀ§·Î ÀüÀÌµÉ °¡´É¼ºÀÌ ÀÖ´Â Áúº´ÀÔ´Ï´Ù. ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¾¾ç ÇÁ·ÎÆÄÀϸµ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡ÇÏ¿© Àǻ簡 Áúº´ÀÇ ½É°¢¼ºÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¿¡ º»»ç¸¦ µÐ Àü¹® ±â°üÀÎ ¹Ì±¹ ¾Ï Çùȸ´Â 2024³â ¹Ì±¹¿¡¼­ 200¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÇ¸ç, ÀÌ´Â 2023³â 190¸¸ ¸í¿¡¼­ Áõ°¡ÇÑ ¼öÄ¡¶ó°í º¸°íÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Àü ¼¼°è¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áõ°¡Çϸ鼭 ¾Ï ¹× Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼ ¹× Covid¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.

The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.12 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (AI) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

The forecast of 13.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. precision medicine by restricting access to multi-omic profiling services and Artificial intelligence(AI)-based tumor analysis software imported from Canada and Sweden, potentially compromising personalized therapy selection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.

The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.

Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformite Europeenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.

In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.

In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cancer tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cancer Tumor Profiling Market Characteristics

3. Cancer Tumor Profiling Market Trends And Strategies

4. Cancer Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cancer Tumor Profiling Growth Analysis And Strategic Analysis Framework

6. Cancer Tumor Profiling Market Segmentation

7. Cancer Tumor Profiling Market Regional And Country Analysis

8. Asia-Pacific Cancer Tumor Profiling Market

9. China Cancer Tumor Profiling Market

10. India Cancer Tumor Profiling Market

11. Japan Cancer Tumor Profiling Market

12. Australia Cancer Tumor Profiling Market

13. Indonesia Cancer Tumor Profiling Market

14. South Korea Cancer Tumor Profiling Market

15. Western Europe Cancer Tumor Profiling Market

16. UK Cancer Tumor Profiling Market

17. Germany Cancer Tumor Profiling Market

18. France Cancer Tumor Profiling Market

19. Italy Cancer Tumor Profiling Market

20. Spain Cancer Tumor Profiling Market

21. Eastern Europe Cancer Tumor Profiling Market

22. Russia Cancer Tumor Profiling Market

23. North America Cancer Tumor Profiling Market

24. USA Cancer Tumor Profiling Market

25. Canada Cancer Tumor Profiling Market

26. South America Cancer Tumor Profiling Market

27. Brazil Cancer Tumor Profiling Market

28. Middle East Cancer Tumor Profiling Market

29. Africa Cancer Tumor Profiling Market

30. Cancer Tumor Profiling Market Competitive Landscape And Company Profiles

31. Cancer Tumor Profiling Market Other Major And Innovative Companies

32. Global Cancer Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Tumor Profiling Market

34. Recent Developments In The Cancer Tumor Profiling Market

35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â